Supernus Pharmaceuticals (SUPN)

Supernus is best known for a neuroscience product lineup that includes Trokendi XR and Oxtellar XR for epilepsy, Qelbree for ADHD, and several medicines serving movement-disorder markets. Its portfolio also includes APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER, among other branded products. These treatments give the company exposure to both paediatric and adult patient populations, as well as to chronic conditions where long-term disease management and physician familiarity are important commercial factors.

The company’s business model combines internal drug development with lifecycle management and selective acquisitions or licensing. Supernus has historically emphasised differentiated formulations, extended-release technologies, and targeted commercial execution in specialist-prescribed therapeutic areas. That focus allows it to compete in markets where clinical profile, dosing convenience, reimbursement access, and relationships with neurologists, psychiatrists, and other specialists can influence adoption.

For investors, Supernus represents a mid-sized pharmaceutical business tied to the performance of branded CNS medicines, pipeline development, regulatory outcomes, patent protection, and competition from both branded and generic alternatives. Its distinctive position lies in its concentrated neuroscience expertise and its mix of established commercial products with newer growth drivers in ADHD and movement disorders.